I Was Skeptical About The Liquid I.V. Electrolyte Sachets — Now I Carry Them Everywhere
After years of taking workout classes, sweating through gym sessions, and stationary biking at home, I've realized how big a role hydration plays in my performance. Since I can't chug litres of water while working out, at least without making myself feel queasy, I've relied on electrolytes to help see me through. The downside? They're usually packed with sugar and unnecessary additives.
When I heard about Liquid I.V. Electrolyte Drink Mixes and took a dip into its reviews, I must admit, I was influenced.
Amazon If you've never dabbled in the world of electrolyte drink mixes, you're in for a treat. Liquid I.V. functions like Gatorade or Powerade, but with much less sugar—a standard bottle of Gatorade has 36 grams of sugar, whereas one sachet of Liquid I.V. has 11 grams. It enhances hydration through five essential vitamins and nutrients, and the blends are scientifically formulated to restore your electrolyte balance, helping you stay hydrated through training, sweating, hot weather, and travelling.
Let's get into the details. Each sachet of Liquid I.V. Electrolyte Drink Mix is 50 calories, containing 13 grams of carbohydrates, 11 grams of sugar, and 500 milligrams of sodium. They also include vitamins B3, B5, B6, and vitamin C. All blends skip GMOs, artificial colours, and artificial flavours, too.
There are currently five flavours available, most inspired by fruits. The brand sometimes introduces limited-edition seasonal flavours, like the Firecracker mix for summer. If you're curious, here's what we're currently working with:
Firecracker
Lemon Lime
Passion Fruit
Strawberry
Tropical Punch
Now, just to warn you, these mixes pack a punch in the flavour department. I'm not a huge fan of the strawberry flavour, but I'm a hater of artificial strawberry, so that should come as no surprise. Firecracker, Tropical Punch, and Passionfruit are definitely the winners in my book. Tropical Punch has notes of tangerine nectar, pineapple and cherry flavours, while Firecracker tastes like the classic tri-tone popsicle, with notes of lemon lime, cherry, and raspberry.
As I mentioned, the flavours are quite strong, so if you're looking to just get a hint of flavour, you'll want to add more water to offset the taste. The recommended ratio is one sachet of Liquid I.V. per 500 millilitres of water, but the ratio really is up to you.
In terms of texture, these mixes get a 10/10. They blend like a dream, with no clumping or graininess left behind after a quick shake (I usually dump them in my Owala water bottle).
What reviewers are saying about the Liquid I.V. Electrolyte Drink Mixes:
While packaging isn't my first priority when it comes to choosing an electrolyte powder, I appreciate that these come in individually portioned packs instead of a scoopable tub. This means you can just grab and go, and bring extra for when you need them (this is especially great for travelling). Each bag comes with 18 sachets, so it'll last you a while. I do wish the sachets were recyclable because they do lead to excess waste.All in all, the Liquid I.V. Electrolyte Drink Mixes are a simple way to boost hydration when exercising or during the hottest months of the year, when you're sweating more than usual. They mix easily, leaving no clumps or graininess behind, and the flavours, at least in my opinion, are delicious.
The electrolyte drink mixes from Liquid I.V. are climbing up the bestseller charts, and reviewers are loving them. They have an impressive rating of 4.3 stars, and people are overwhelmingly impressed by the taste and their boosted hydration. They also love that they come in pre-portioned packs, making them easy to throw in their bags and go. Some find the flavours too strong and others don't like the added sugar, but most agree that they're delicious and easy to work into any routine.
And if you aren't done shopping, here are a few more health & fitness products worth adding to your cart:
Here's Everything You Should Pack In Your Gym Bag
The Absolute Best Pill Organizers You Can Get In Canada Right Now
This Is the Only Plant-Based Protein Powder I Actually Enjoy — And It's Canadian
Disclaimer: The prices displayed are accurate at the time of publication. We'll do our best to keep them as up-to-date as possible, but you may see slight changes.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
2 hours ago
- CBC
Regular cannabis use can cause a serious vomiting syndrome. Should people be warned?
When Brittany Ramsey started experiencing "awful stomach episodes" she thought it must've been side effects of the medication she was taking to manage her diabetes. But after a particularly gruelling episode where she just could not stop vomiting — not being keep down even small sips of water — that landed her in hospital, Ramsey knew something felt different about what she was experiencing. "From then, the episodes got worse and worse, and closer together," said Ramsey, a 35-year-old operations trainer at a financial firm in Cincinnati, Ohio. "From 2021 to 2024 … three years, I was hospitalized 29 times. Five ambulance trips – one actually had to pick me up on the side of the road because I couldn't make it to the hospital." After years of undergoing, at times, invasive testing procedures to rule out Crohn's disease, gastroparesis and diverticulitis, a doctor told Ramsey about cannabis hyperemesis syndrome (CHS). In recent years some emergency rooms have been seeing an uptick in visits due to cyclic episodes of uncontrollable vomiting in cannabis users, often characterized by experiencing temporary relief with hot showers and baths. Since it was first identified in medical literature in 2004, CHS cases have increased, possibly because of greater cannabis access or higher THC potency of products. Public health researchers suggest more awareness of CHS within the health-care system is needed for cannabis users to get the information and support they need. More CHS cases in the ER CHS is characterized by "severe and persistent vomiting" and is usually seen in people who have been using cannabis several times a week for multiple years, said Jamie Seabrook, a professor at the Department of Epidemiology and Biostatistics at Western University in London, Ont. Ramsey said she'd been smoking at least once a day for over 10 years since she was 18 when she first started experiencing CHS symptoms in 2017. A 2022 study by researchers at the Ottawa Hospital Research Institute looked at the rate of emergency department visits for CHS after recreational cannabis was legalized and commercialized in Ontario, looking at nearly 13,000 CHS-related hospitalizations in Ontario from 8,140 individuals between 2014 and 2021. The study, published in the Journal of the American Medical association (JAMA), found that emergency department visits related to CHS had increased by 13-fold over a period of nearly eight years. The study doesn't show what caused the change, but the authors noted that the biggest increase in visits came not after legalization in 2018 but after Ontario allowed expansion of retail stores in 2020, which coincided with the COVID-19 pandemic. Though we don't have numbers how many people have been diagnosed or hospitalized with CHS, online communities are filled with people looking for support. Ramsey is part of one of them — a CHS Facebook group described as a "safe place to recover and learn" with 3,000 members. The largest CHS Facebook group has 31,000 members. On Reddit, the group r/CHSinfo has 20,000 members, with discussions ranging from tips on how to manage episodes and personal anecdotes about repeated hospitalizations. Seabrook, who co-authored a recent review of existing research on CHS in youth, said there's been an "explosion" of people showing up in some North American emergency rooms with CHS within the last seven to eight years. The Ottawa Hospital Research Institute study showed that other cannabis-related emergency room visits, including for intoxication and dependence, saw a substantial increase starting in early 2020 as well. Surge in THC potency since the 1980s Seabrook said a likely reason for increased rates of CHS is the high THC potency of cannabis products today. THC is the compound in cannabis that is responsible for the sensation of a high most people experience when consuming it. When its potency increases, so do its harmful effects. Different strains of the plant will have different concentrations of active compounds, measured by percentage of total weight or volume. On average, THC content is much higher today than it used to be. "The potency of THC was only about three per cent in the 1980s and today, according to Health Canada, the average is 15 per cent with some strains as high as 30 per cent," Seabrook said, citing Health Canada numbers for "fresh or dried herb material." "So we're talking a 400 per cent or higher increase in the potency." For "chemically concentrated extracts," such as hash oil, shatter, budder and wax, the typical potency can be up to 90 per cent, according to Health Canada data. "The potency, I think, is what's causing the illnesses to become more and more prevalent, because they're smoking a lot more potent stuff," Ramsey said. "And that's the same with me. When I first started smoking, it was my brother's homegrown stuff, versus getting it from friends and dispensaries out in California, where it does get stronger and stronger." "I feel like maybe before just making marijuana available to the masses, maybe some of these things should have been looked into. You know, too much of anything might be bad," said Ramsey. Lawsuit against Aurora Cannabis cites CHS A lawsuit was recently brought against Canadian cannabis production company Aurora Cannabis for alleged negligence of failing to warn consumers about the potential risk for developing CHS from the regular use of its products. The lawsuit was certified by the Ontario Superior Court of Justice last month, meaning it can proceed as a class action. Margaret Waddell, the lawyer prosecuting the case, said she hopes that if the lawsuit is successful, it could have an industry-wide effect on including CHS in their product labelling. "Ideally, Health Canada will require them at some point," Waddell said. Health Canada does require cannabis manufacturers to warn customers about specified risks — including psychotic symptoms, addiction and dependence — but Waddell said there aren't currently any requirements to specifically include CHS in those warnings. Aurora Cannabis declined to comment on the lawsuit, writing in an emailed statement: "It is the company's practice not to comment on legal matters beyond information that is made available to the public." "Information that [CHS] exists is very important," Seabrook said. "In schools, in health-care settings – whether that's neurologists, psychiatrists, [emergency room] doctors – and public health campaigns, so people can make a better informed decision about their cannabis use."
Globe and Mail
8 hours ago
- Globe and Mail
Top FDA official restricted COVID vaccine approvals against advice of agency staff
The government's top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding recommendations from government scientists, according to federal documents released Wednesday. The new memos from the Food and Drug Administration show how the agency's vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and Moderna. Both vaccines were approved by the FDA in May after months of analysis by rank-and-file FDA reviewers. But internal correspondence show Prasad disagreed with staffers who planned to approve the shots for everyone 12 and older, similar to previous COVID vaccines. The scientists had concluded the benefit from the vaccines and the risk of COVID-19 outweighed the risk of possible side effects, which are rare. Instead Prasad decided the shots should be limited to those who face special risks from the virus — seniors or children and adults with underlying medical issues. Prasad explained that the COVID vaccine benefits must be reconsidered in light of falling rates of death and hospitalization and the possibility for vaccine side effects. It's the latest in a series of vaccine restrictions imposed by officials working under Kennedy, who has long questioned the benefits of vaccines. 'Even rare vaccination related harms both known and unknown now have higher chance of outweighing potential benefits' Prasad wrote in a five-page memo explaining his decision. COVID-19 remains a public health threat, resulting in 32,000 to 51,000 U.S. deaths and more than 250,000 hospitalizations since last fall, according to the Centers for Disease Control and Prevention. Most at risk for hospitalization are seniors and children under 2 — especially infants under 6 months. Top FDA leaders are typically not involved in the review of individual products. Officials like Prasad can overrule staffers, but such cases are rare and often controversial. News of the FDA documents was first reported by the New York Times. Prasad was hired to lead the FDA's vaccine center in May, after the previous director, Dr. Peter Marks, was forced to resign over disagreements with Kennedy. An academic researcher specializing in cancer therapies, Prasad came to prominence during the pandemic for criticizing public health measures, including the FDA's approval of COVID boosters for healthy adults and children. Since arriving at the agency he has worked with FDA Commissioner Mark Makary on new guidelines that will limit approvals of future COVID boosters to higher-risk Americans, mainly seniors and those with medical conditions like asthma and obesity. Those limits match the terms FDA recently approved for Novavax's shot, Nuvaxovid and Moderna's mNexspike. Novavax's vaccine is the only protein-based coronavirus vaccine available in the U.S. Moderna's vaccine is an updated, lower-dose version of its existing mRNA-based vaccine. The review team for the Novavax vaccine pointed to data from a study in 30,000 adults, concluding that 'the risk-benefit assessment for this vaccine technology remains favorable.' FDA staff reached a similar conclusion for the Moderna vaccine, deeming it similar in safety and effectiveness to the company's original shot. Science under siege: The rise of the wellness-conspiracy-prosperity gospel Last week, the FDA finalized new warning labeling about the risk of myocarditis, a rare form of heart inflammation, on shots from Moderna and Pfizer, the other maker of an mRNA-based shot for COVID. In his 'override memo,' reversing FDA staff's decision on the Moderna shot, Prasad pointed to the ongoing risk of myocarditis and questions about its frequency. The agency ordered Moderna to conduct further studies of the risk as a condition for the approving its updated shot. A spokesman for the administration said Prasad 'has raised serious concerns' about the issue. 'We will not ignore these risks and will ensure that the gold standard of science is used for any decisions,' said Andrew Nixon, in an emailed statement. Outside researchers have noted that cases of the heart condition tend to resolve quickly and are less severe than those associated with COVID infection itself, which can also cause myocarditis.
Globe and Mail
11 hours ago
- Globe and Mail
Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Hepatitis D Pipeline Insight, 2025 ' report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Hepatitis D pipeline landscape. It covers the Hepatitis D pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis D pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Hepatitis D Pipeline. Dive into DelveInsight's comprehensive report today! @ Hepatitis D Pipeline Outlook Key Takeaways from the Hepatitis D Pipeline Report In June 2025, Ribocure Pharmaceuticals AB announced clinical trial is to learn if drug RBD1016 works to treat chronic hepatitis D virus infection in adults. It will also learn about the safety of drug RBD1016. There will be 2 treatment groups - an active group (n=10) and a deferred active group (n=5), with participants allocated randomly. In the active group, participants will receive RBD1016. In the deferred active group, participants will receive 4 doses of placebo followed by deferred treatment with doses of RBD1016. In June 2025, Vir Biotechnology Inc. conducted Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment. DelveInsight's Hepatitis D Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Hepatitis D treatment. The leading Hepatitis D Companies such as Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others. Promising Hepatitis D Pipeline Therapies such as Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others. Stay ahead with the most recent pipeline outlook for Hepatitis D. Get insights into clinical trials, emerging therapies, and leading companies with Hepatitis D @ Hepatitis D Treatment Drugs Hepatitis D Emerging Drugs Profile Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes, and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart, which incorporates Xencor's Xtend™ and other Fc technologies, has been engineered to have an extended half-life and was identified using Vir Biotechnology's proprietary monoclonal antibody discovery platform. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicates that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. It is the first asset in Vir Biotechnology's collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical studies. Currently, this combination drug product is in Phase III stage of its development for the treatment of Hepatitis D. Brelovitug: Bluejay Therapeutics Brelovitug is an investigational, highly potent, pan-genotypic, fully human IgG1 mAb that targets the anti-HBsAg on both the HDV and the HBV. Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which gives brelovitug a potentially advantageous safety profile and makes it a potentially efficacious treatment for CHD, a condition with urgent unmet medical need. In addition, brelovitug has shown immunomodulatory functions in CHB patients, which may help to reconstitute antiviral immunity and contribute to functional cure for CHB when combined with other agents. Currently, the drug is in the Phase II/III stage of its development for the treatment of Hepatitis D. RBD1016: Ribocure Pharmaceuticals AB RBD1016 is a GalNAc-siRNA drug independently developed by Ribo based on its proprietary GalNAc-siRNA platform, targeting the X gene of hepatitis B virus. It inhibits all four HBV transcripts through the RNA interference mechanism, and can simultaneously inhibit HBV DNA replication, reduce cccDNA and integrate DNA derived HBsAg and other antigens. RBD1016 demonstrates well-tolerated safety profile in Phase I study including both healthy subjects and patients with CHB infection. RBD1016 shows a highly efficient long-acting effect of reducing the HBsAg in patients. Currently, the drug is in Phase II stage of its development for the treatment of Hepatitis D. The Hepatitis D Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis D with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D Treatment. Hepatitis D Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Hepatitis D Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis D market Explore groundbreaking therapies and clinical trials in the Hepatitis D Pipeline. Access DelveInsight's detailed report now! @ New Hepatitis D Drugs Hepatitis D Companies Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others. Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Hepatitis D Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Hepatitis D Treatment. Learn about new drugs, Hepatitis D Pipeline developments, and key companies with DelveInsight's expert analysis @ Hepatitis D Market Drivers and Barriers Scope of the Hepatitis D Pipeline Report Coverage- Global Hepatitis D Companies- Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others. Hepatitis D Pipeline Therapies- Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others. Hepatitis D Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Hepatitis D Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Hepatitis D Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hepatitis D Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Hepatitis D: Overview Pipeline Therapeutics Therapeutic Assessment Hepatitis D– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals Drug profiles in the detailed report….. Mid Stage Products (Phase II/III) Brelovitug: Bluejay Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug Name: Company Name Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Hepatitis D Key Companies Hepatitis D Key Products Hepatitis D- Unmet Needs Hepatitis D- Market Drivers and Barriers Hepatitis D- Future Perspectives and Conclusion Hepatitis D Analyst Views Hepatitis D Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
